Scilex Holding Company announced the publication of data on GLOPERBA® dosing adjustments in a peer-review journal. GLOPERBA® is the first and only liquid oral version of colchicine for the prophylaxis of painful gout flares in adults.
The publication highlights GLOPERBA's ability to allow for precision dosing and reduction of daily dose in patients with severe renal impairment, a critical factor as over 70% of gout patients have comorbid conditions requiring dose adjustments.
Analysis of pharmacokinetic model data demonstrated that precise dosing with colchicine oral solution, specifically 0.48 mg for moderate and 0.3 mg for severe renal impairment, is associated with optimal therapeutic levels and greater safety, addressing risks of toxicity with standard solid dosage formulations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.